Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Detecting the "scent" of ovarian cancer with AI

23

Feb 2026

Detecting the "scent" of ovarian cancer with AI

Using machine learning, an electronic nose can "smell" early signs of ovarian cancer in the blood. The method is precise and, according to the LiU researchers behind the study, it could eventually be used to find many different cancers. The study is published in the scientific journal Advanced intelligent systems.

Unmasking the impact of C. neoformans as a Global Menace

23

Feb 2026

Unmasking the impact of C. neoformans as a Global Menace

Cryptococcus neoformans is one of four fungi classified as 'critical priority' on the WHO's Fungal Pathogens Priority List, which was published in October 2022 following decades of research and calls for fungal pathogens to be classified alongside their bacterial and viral counterparts.

Rethinking cardiovascular risk assessment in women

23

Feb 2026

Rethinking cardiovascular risk assessment in women

Less artery-clogging plaque in women's arteries did not appear to protect them from heart disease compared to men, according to a study published in Circulation: Cardiovascular Imaging, an American Heart Association journal.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.